Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | mouse |
isotype | IgM |
clonality | monoclonal |
concentration | concentrate, predilute |
applications | IHC |
reactivity | human |
available size | 0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted |
mouse anti-CD15 monoclonal antibody (MMA) 6064
$160.00 – $528.00
Antibody summary
- Mouse monoclonal to CD15
- Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
- Reacts with: Human
- Isotype:IgM
- Control: Hodgkin lymphoma
- Visualization: Cell membrane and granular perinuclear
- 0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted
mouse anti-CD15 monoclonal antibody MMA 6064
target relevance |
---|
Protein names Alpha-(1,3)-fucosyltransferase 4 (4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase) (EC 2.4.1.152) (ELAM-1 ligand fucosyltransferase) (Fucosyltransferase 4) (Fucosyltransferase IV) (Fuc-TIV) (FucT-IV) (Galactoside 3-L-fucosyltransferase) |
Protein family Glycosyltransferase 10 family |
Mass 59084Da |
Function [Isoform Short]: Catalyzes alpha(1->3) linkage of fucosyl moiety transferred from GDP-beta-L-fucose to N-acetyl glucosamine (GlcNAc) within type 2 lactosamine (LacNAc, Gal-beta(1->4)GlcNAc) glycan attached to N- or O-linked glycoproteins (PubMed:1702034, PubMed:1716630, PubMed:29593094). Robustly fucosylates nonsialylated distal LacNAc unit of the polylactosamine chain to form Lewis X antigen (CD15), a glycan determinant known to mediate important cellular functions in development and immunity. Fucosylates with lower efficiency sialylated LacNAc acceptors to form sialyl Lewis X and 6-sulfo sialyl Lewis X determinants that serve as recognition epitopes for C-type lectins (PubMed:1716630, PubMed:29593094). Together with FUT7 contributes to SELE, SELL and SELP selectin ligand biosynthesis and selectin-dependent lymphocyte homing, leukocyte migration and blood leukocyte homeostasis (By similarity). In a cell type specific manner, may also fucosylate the internal LacNAc unit of the polylactosamine chain to form VIM-2 antigen that serves as recognition epitope for SELE (PubMed:11278338, PubMed:1716630). .; [Isoform Long]: Does not generate Lewis X antigens. . |
Catalytic activity CATALYTIC ACTIVITY: [Isoform Short]: Reaction=a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + GDP-beta-L-fucose = a beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl derivative + GDP + H(+); Xref=Rhea:RHEA:14257, ChEBI:CHEBI:15378, ChEBI:CHEBI:57273, ChEBI:CHEBI:58189, ChEBI:CHEBI:133507, ChEBI:CHEBI:137941; EC=2.4.1.152; Evidence=; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14258; Evidence=; CATALYTIC ACTIVITY: [Isoform Short]: Reaction=an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+); Xref=Rhea:RHEA:56076, ChEBI:CHEBI:15378, ChEBI:CHEBI:57273, ChEBI:CHEBI:58189, ChEBI:CHEBI:136545, ChEBI:CHEBI:139509; Evidence=; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56077; Evidence=; CATALYTIC ACTIVITY: [Isoform Short]: Reaction=an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc derivative + GDP + H(+); Xref=Rhea:RHEA:68044, ChEBI:CHEBI:15378, ChEBI:CHEBI:57273, ChEBI:CHEBI:58189, ChEBI:CHEBI:145343, ChEBI:CHEBI:176900; Evidence=; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:68045; Evidence=; CATALYTIC ACTIVITY: Reaction=an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc6S derivative + GDP-beta-L-fucose = an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6S derivative + GDP + H(+); Xref=Rhea:RHEA:62004, ChEBI:CHEBI:15378, ChEBI:CHEBI:57273, ChEBI:CHEBI:58189, ChEBI:CHEBI:145344, ChEBI:CHEBI:145345; Evidence=; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:62005; Evidence=; |
Pathway PATHWAY: [Isoform Short]: Protein modification; protein glycosylation. . |
Subellular location Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Note=Membrane-bound form in trans cisternae of Golgi. |
Tissues [Isoform Short]: Expressed at low levels in bone marrow-derived mesenchymal stem cells. .; Expressed in cord blood immature promyelocytes and in peripheral blood myeloid and lymphoid cell populations. . |
Target Relevance information above includes information from UniProt accession: P22083 |
The UniProt Consortium |
Data
Human Hodgkin lymphoma stained with anti-CD15 antibody using peroxidase conjugate and DAB chromogen. Note membranous staining of Reed-Sternberg cells. |
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.pmid | title | authors | citation |
---|
Protocols
relevant to this product |
---|
IHC |
Documents
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.